Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $527.01, for a total transaction of $5,006,595.00. Following the transaction, the chief executive officer owned 40,513 shares in the company, valued at $21,350,756.13. The trade was a 19.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

United Therapeutics Stock Performance

UTHR stock opened at $531.82 on Wednesday. The company has a market capitalization of $23.31 billion, a PE ratio of 19.06, a price-to-earnings-growth ratio of 1.88 and a beta of 0.84. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $548.12. The company’s 50 day moving average price is $492.27 and its two-hundred day moving average price is $470.84.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The company had revenue of $790.20 million during the quarter, compared to analysts’ expectations of $814.80 million. During the same quarter in the prior year, the company earned $6.19 EPS. The firm’s revenue was up 7.4% on a year-over-year basis. On average, research analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current year.

Wall Street Analyst Weigh In

UTHR has been the topic of a number of recent research reports. Royal Bank Of Canada raised their price objective on United Therapeutics from $587.00 to $643.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Cantor Fitzgerald boosted their target price on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research note on Thursday, March 12th. UBS Group increased their target price on United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a report on Thursday, March 5th. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. Nine investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $549.91.

Hedge Funds Weigh In On United Therapeutics

A number of hedge funds have recently modified their holdings of the company. Torren Management LLC bought a new position in shares of United Therapeutics during the fourth quarter valued at about $26,000. Activest Wealth Management grew its stake in shares of United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 56 shares during the last quarter. WealthCollab LLC increased its holdings in United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 38 shares during the period. Rakuten Securities Inc. increased its holdings in United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 46 shares during the period. Finally, Entrust Financial LLC bought a new position in United Therapeutics during the 4th quarter valued at approximately $31,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.